Pure Global AI
NCT06406348Not yet recruiting

A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-1758 in Healthy Participants

A Randomized, Double-Blind, Placebo-Controlled, Phase 1, Single Ascending Dose Trial to Assess the Safety, Tolerability and Pharmacokinetic Effects of ALIA-1758 in Healthy Participants
Aliada TherapeuticsPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Alzheimer Disease
Drug/Device/Intervention
ALIA-1758
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Aliada Therapeutics
Location
San Antonio, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
May 01, 2024
End date
Dec 01, 2024
Enrollment
52 participants
Primary outcome

Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

Summary

This is a Phase 1, first in human (FIH), double-blind, placebo-controlled, single ascending
 dose (SAD) trial to assess the safety, tolerability, and pharmacokinetics (PK) of
 intravenously (IV) or subcutaneously (SC) injected ALIA-1758 in healthy male and female
 participants.

ICD-10 classifications
Alzheimer diseaseAlzheimer disease, unspecifiedOther Alzheimer diseaseDementia in Alzheimer diseaseDementia in Alzheimer disease, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06406348
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06406348 through Pure Global AI's free database. This Phase 1 trial is sponsored by Aliada Therapeutics and is currently Not yet recruiting. The study focuses on Alzheimer Disease. Target enrollment is 52 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.